Pre-Made Alvircept Sudotox biosimilar, Fusion Protein: Recombinant therapeutic protein targeting HIV-1 gp120 fused with Pseudomonas aeruginosa exotoxin A is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Alvircept sudotox is a form of recombinant CD4 derived from Pneumonas aeruginosa exotoxin A, or ‘PE4, which has a size of 59,187 daltons and is an anti-viral agent.[1]
Alvircept sudotox is a form of recombinant CD4 derived from Psedomonas aeruginosa exotoxin A, or ‘PE40¡¯ as an anti-viral agent. Alvircept Sudotox has been used in trials studying the treatment of HIV Infections.